Marshall Wace
CTNM

Marshall Wace’s Contineum Therapeutics CTNM Stock Holding History

Marshall Wace’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.96M Buy
226,302
+45,498
+25% +$610K ﹤0.01% 1573
2025
Q4 		$2.07M Sell
180,804
-12,687
-7% -$145K ﹤0.01% 1565
2025
Q3 		$2.27M Buy
193,491
+164,806
+575% +$1.33M ﹤0.01% 1553
2025
Q2 		$114K Sell
28,685
-2,399
-8% -$10.4K ﹤0.01% 2529
2025
Q1 		$217K Buy
31,084
+20,248
+187% +$184K ﹤0.01% 2377
2024
Q4 		$159K Buy
+10,836
New +$172K ﹤0.01% 2390

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace's CTNM Position: Q1 2026 in Review

Marshall Wace increased its Contineum Therapeutics (CTNM) stake by 25% in Q1 2026, buying an estimated $610K and bringing the position to 226,302 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

Marshall Wace first reported a position in CTNM in Q4 2024 and has held it in 6 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Marshall Wace held 226,302 shares of Contineum Therapeutics worth $2.96M as of Q1 2026.
  • Marshall Wace bought 45,498 Contineum Therapeutics shares in Q1 2026, an estimated $610K.
  • Contineum Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1573 holding.
  • Marshall Wace first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.